957 reports of this reaction
1.5% of all ATOMOXETINE HYDROCHLORIDE reports
#16 most reported adverse reaction
ABNORMAL BEHAVIOUR is the #16 most commonly reported adverse reaction for ATOMOXETINE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 957 FDA adverse event reports linking ATOMOXETINE HYDROCHLORIDE to ABNORMAL BEHAVIOUR. This represents approximately 1.5% of all 63,960 adverse event reports for this drug.
Patients taking ATOMOXETINE HYDROCHLORIDE who experience abnormal behaviour should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABNORMAL BEHAVIOUR is a less commonly reported adverse event for ATOMOXETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to abnormal behaviour, the following adverse reactions have been reported for ATOMOXETINE HYDROCHLORIDE:
The following drugs have also been linked to abnormal behaviour in FDA adverse event reports:
ABNORMAL BEHAVIOUR has been reported as an adverse event in 957 FDA reports for ATOMOXETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABNORMAL BEHAVIOUR accounts for approximately 1.5% of all adverse event reports for ATOMOXETINE HYDROCHLORIDE, making it a notable side effect.
If you experience abnormal behaviour while taking ATOMOXETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.